Free Access
Med Sci (Paris)
Volume 31, Number 5, Mai 2015
Page(s) 473 - 475
Section Nouvelles
Published online 09 June 2015
  1. Bruchard M, Ghiringhelli F. Microenvironnement tumoral : cellules régulatrices et cytokines immunosuppressives. Med Sci (Paris) 2014 ; 30 : 429–435. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Galon J, Bindea G, Mlecnik B, et al. Microenvironnement immunitaire et cancer : intérêt de l’immunoscore pour prédire l’évolution clinique. Med Sci (Paris) 2014 ; 30 : 439–444. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol 2014 ; 4 : 70. [CrossRef] [PubMed] [Google Scholar]
  4. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009 ; 69 : 2514–2522. [CrossRef] [PubMed] [Google Scholar]
  5. Gavalas NG, Tsiatas M, Tsitsilonis O, et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer 2012 ; 107 : 1869–1875. [CrossRef] [PubMed] [Google Scholar]
  6. Ziogas AC, Gavalas NG, Tsiatas M, et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. Int J Cancer 2012 ; 130 : 857–864. [CrossRef] [PubMed] [Google Scholar]
  7. Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015 ; 212 : 139–148. [CrossRef] [PubMed] [Google Scholar]
  8. Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013 ; 73 : 128–138. [CrossRef] [PubMed] [Google Scholar]
  9. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009 ; 10 : 29–37. [CrossRef] [PubMed] [Google Scholar]
  10. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 ; 32 : 1020–1030. [CrossRef] [PubMed] [Google Scholar]
  11. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010 ; 11 : 155–164. [CrossRef] [PubMed] [Google Scholar]
  12. Robert C, Mateus C. Anticorps anti-CTLA-4 : une avancée thérapeutique majeure dans le traitement du mélanome métastatique. Med Sci (Paris) 2011 ; 27 : 850–858. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.